Skip to main content

Spexis receives capital commitment of 2.5 million US dollars

| News

Spexis receives capital commitment of 2.5 million US dollars


Investors have made an additional capital commitment to Spexis AG, based in the Basel Area. With an extra 2.5 million US dollars at its disposal, the biopharmaceutical firm plans to finance a Phase 3 study for its inhaled therapeutic to treat chronic infections in cystic fibrosis patients.


The biopharmaceutical company Spexis, based in Allschwil in the canton of Basel-Landschaft, has announced that it has received a capital commitment totaling 2.5 million US dollars. According to a press release, both SPRIM Global Investments and institutional investors were involved in the process. With this, funding for the upcoming Phase 3 study in ColiFin, an inhaled macrocycle therapeutic for the management of chronic infections in cystic fibrosis patients, has now been secured.

“This new capital allows us to not only initiate the COPILOT study in the third quarter, but will also allow for continued progress across start-up activities for COPA, the second part of our planned pivotal efficacy and safety Phase 3 study”, as Jeff Wager, Chairman and CEO of Spexis, explains in the press release. In Europe, the drug has been approved as a first-line therapy for lung infections since 2010. Approval is now being sought for the US market.

Spexis emerged from Polyphor

In April of this year, Spexis already secured fresh capital in the amount of 4.5 million US dollars from SPRIM Global Investments, which will enable the company to start its Phase 3 COPILOT study, the first of two planned ColiFin studies, as Spexis explains in a press release.

Spexis was formed out of the Allschwil-based biotech company Polyphor, with the change of name at the beginning of 2022 coming as a consequence of the acquisition of Polyphor by the biotech company Enbiotix, which is based in Cambridge, Massachusetts. Since this time, Enbiotix has held a stake of 75 percent in Spexis. The most promising drug candidate in the pipeline, ColiFin, comes from Enbiotix.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

biGENIUS receives 2 million euros for new cloud product

Software company biGENIUS, based in the Basel Area, has secured financing of 2 million euros. This funding was granted following...
Read More

Opterion Health secures investment of 6.5 million Swiss francs

Opterion Health has raised a total of 6.5 million Swiss francs as part of a financing round. The company, which...
Read More

TOLREMO receives 39 million US dollars in investments

TOLREMO Therapeutics has concluded a series A funding round with 39 million US dollars. The biotech company based in Basel...
Read More

Mazars opens tenth Swiss office in Basel

Mazars is now also present in Basel with a subsidiary as of September 1. This is the tenth Swiss location...
Read More

Medtech in Switzerland – bringing together traditional skills and hightech industry

How the intersection of traditional and novel skillsets in the Jura area is propelling Switzerland into a new era of...
Read More

Fondation Botnar supporting further research into pediatric health

The Basel-based Botnar Research Centre for Child Health has received a further donation of 50 million Swiss francs from the...
Read More

Do you have a question? We'd like to hear from you.